Table 1 Main demographic, clinical and serological characteristics of the study population

Patients [n (%)]

58

90

28

–

Pneumonia cases [n (%)]

39 (67.2)

90 (100)

0 (0)

< 0.001

SARS-CoV-2 IgM+ cases [n (%)]

10 (17.2)

0 (0)

0 (0)

< 0.001

SARS-CoV-2 IgG+ cases [n (%)]

49 (84.5)

86 (95.6)

25 (89.3)

ns

SARS-CoV-2 IgG RBD+ cases [n (%)]

35 (60.3)

84 (93.3)

25 (89.3)

ns

SARS-CoV-2 IgM [AU/mL]

9.55 ± 22.61

0.84 ± 1.38

1.84 ± 2,60

0.0043

SARS-CoV-2 IgG [AU/mL]

688.2 ± 954.0

1099.1 ± 990.8

1149.0 ± 1162.0

0.0342

SARS-CoV-2 IgG RBD [AU/mL]

334.2 ± 383,0

437.1 ± 447.1

364.3 ± 369.8

ns

Age [years]

57.2 ± 14.1

49.8 ± 16.3

50.9 ± 18.3

0.0206

Gender—F/M [n]

39/19

57/33

16/12

ns

SARS-CoV-2 vaccinated pts. [n (%)]

29 (50.0)

53 (58.9)

11 (39.3)

ns

Chronic comorbidities

 Cardiovascular diseases [n (%)]

31 (53.4)

43 (47.8)

28 (100)

0.0057

  Primary cardiomyopathy

3 (5.2)

2 (2.2)

9 (32.1)

0.0001

  Ischemic cardiomyopathy

7 (12.1)

8 (8.9)

12 (42.8)

0.0002

  Hypertension

29 (50.0)

40 (44.4)

19 (67.8)

ns

  Cardiac arrhythmias

4 (6.9)

4 (4.4)

9 (32.1)

0.0002

  Congenital heart disease

0 (0%)

0 (0)

6 (21.4)

0.0001

 Metabolic diseases [n (%)]

25 (43.1)

34 (37.8)

8 (28.6)

ns

  Diabetes mellitus type 2

7 (12.1)

613 (14.4)

2 (6.6)

ns

  Obesity

19 (32.8)

29 (32.2)

8 (28.6)

ns

 Respiratory diseases [n (%)]

3 (7.6)

8 (8.9)

1 (3.6)

ns

  Asthma

1 (1.7)

6 (6.7)

1 (3.6)

ns

  COPD

2 (3.4)

2 (2.2)

(0)

ns

 Renal diseases [n (%)]

3 (5.2)

5 (5.6)

4 (13.3)

ns